SAB BIOTHERAPEUTICS INC (SABS)
Health Care · Biotechnology · NASDAQ
SAB Biotherapeutics is developing a platform of transchromosomic cattle to produce fully human, high-potency polyclonal antibodies to treat autoimmune diseases like Type 1 Diabetes.
What SAB BIOTHERAPEUTICS INC does
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing multi-specific, human immunoglobulin G (hIgG) therapeutics for immune and autoimmune disorders. The company utilizes a proprietary transchromosomic cattle (Tc-Bovine) platform to produce high-potency, disease-targeted human antibodies without the need for human plasma donors. Its lead product candidate, SAB-142, is currently in clinical development as a disease-modifying immunotherapy for type 1 diabetes.
Recent developments
In April 2026, the company entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. SAFEGUARD Part A, the dose-ranging portion of the Phase 2b trial for SAB-142, completed enrollment in Q1 2026.
From SAB BIOTHERAPEUTICS INC's filing of 2026-08-06.
Themes: autoimmune diseases / T1D, immunotherapy, antibody therapeutics, biomanufacturing technology
Fundamentals
- Price$2.89 as of 2026-10-08 close
- Market cap$263M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+23.5% 2025-10-08 close $2.34 → 2026-10-08 close $2.89
- P/En/a negative earnings
- ROE+8.8% FY2025, SEC XBRL
- Debt / equity0.01 as of 2026-09-02
- Beta0.90 as of 2026-09-02
- Last reported earnings2024-03-29 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How SABS compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SAB BIOTHERAPEUTICS INC looks technically
SAB BIOTHERAPEUTICS INC (SABS) is trading 23.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 50 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 43.9% below its highest point of the past year. Trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | it is trading 23.3% below its 200-day average, the long-term trend line — a long-term downtrend | -23.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.54 | $3.54 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.77 | $3.77 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 20 calendar days ago — the swings before that are what the structure reading is measured on | 20 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 3.565. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 50 trading days ago — a "death cross", a bearish long-term signal | 50 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with sellers in control | 30.6 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 29, in oversold territory (below 30) | 28.7 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($2.76 to $3.56) — its "stochastic" reading is 16 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 16.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 27 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.15 | $5.15 |
|---|---|---|
| From the 52-week high | it is 43.9% below its 52-week high (its highest price of the past year) | -43.9% |
| Above the 52-week low | it is 51.4% above its 52-week low (its lowest price of the past year) | +51.4% |
| Below the 52-week high | it is 43.9% below its highest point of the past year | 43.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $129.00 (set on 2021-10-22) | $129.00 |
| Given back of the 52-week move | over the past year its closes ranged ($1.98 to $4.59), and it has given back well over two thirds of its rise from last year’s low — 65% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.89 to $2.98. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 65.1% |
| From the all-time high | it is 97.8% below its all-time high | -97.8% |
| Nearest price level | it is trading 10.0% above a support level at $2.60 — a price it turned at twice since 2024-10-25, most recently on 2025-10-09. Since 2024-10-08 it has 7 such levels below the current price and 11 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -10.0% |
| All-time low | its lowest closing price on record is $1.00 (set on 2025-04-04) | $1.00 |
| Above the all-time low | it is 189.0% above its all-time low | +189.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1825 between its high and its low — about 6.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1825 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.84 and $3.67 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.84 – $3.25 – $3.67 |
| Typical daily range (% of price) | its price moves about 6.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.3% |
| Stretch from the 200-day average | it is trading 4.8 daily ranges below its 200-day average price (23.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 2.1× its 30-day average, a sign of heightened interest | 2.09× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
|---|---|---|
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Gap filled | a 2.3% gap down opened on 2026-07-17 has been "filled" 58 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 58 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 21.4 percentage points (the stock lost 20.4% while the market gained 1.0%) | -21.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.2 percentage points (the stock lost 23.3% while the market gained 3.8%) | -27.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 42.4 percentage points (the stock lost 24.9% while the market gained 17.5%) | -42.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 8.5 percentage points (the stock gained 23.5% while the market gained 15.0%) | +8.5% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.3% of the share price, which is taken to mean a barrier that gives way easily. | -22.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 24% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.80 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -24.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $3.41 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -15.3% |
Double top, bearish — broke down · entry $3.44 · 77 sessions in
Price levels it has turned at before
SABS last closed at $2.89 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 11 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.60 | Support | 10.0% below the last close | turned there twice · 2024-10-25 to 2025-10-09 |
| $3.32 | Resistance | 14.7% above the last close | turned there six times · 2024-12-18 to 2026-09-15 |
| $3.41 | Resistance | 17.9% above the last close | turned there three times · 2026-01-12 to 2026-05-19 |
| $2.35 | Support | 18.7% below the last close | turned there twice · 2024-10-15 to 2025-09-03 |
| $3.51 | Resistance | 21.5% above the last close | turned there three times · 2025-12-30 to 2026-07-07 |
| $2.15 | Support | 25.6% below the last close | turned there twice · 2025-02-19 to 2025-05-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $3.56.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $2.48 and $2.90 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $3.56.
This reading has stood for 10 trading days, since 2026-09-25.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Unusually heavy trading volume · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$11.64 range $6.00 – $16.00; median $12.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SABS
- Consensus EPS estimate-$0.2688 next reporting period, as of 2026-10-05
- Estimate change, 30 days$0.00 from -$0.2688, on 2026-08-31, 35-day window
- Readings revised upward0% of 5 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High clinical development risk and uncertainty regarding the efficacy and safety of SAB-142 in registrational trials.","Dependence on a proprietary production platform (Tc-Bovine) that may face technical, regulatory, or operational challenges.","Significant ongoing capital requirements for research and development, with no guarantee of future profitability despite recent financial performance."]
What changed in the latest 10-Q
AI-assisted comparison of SABS's 10-Q filed 2026-05-12 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds: 'potentially disease-modifying' descriptor for SAB-142 in lead product candidate section (filed 2026-05-12)
- Newer filing adds: 'redosable immunotherapy' characteristic for SAB-142 (filed 2026-05-12)
- Newer filing adds: 'multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG)' description (filed 2026-05-12)
- Newer filing adds: 'directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of "bad acting" T-lymphocytes' mechanism detail (filed 2026-05-12)
- Newer filing adds: specific reference to 'data from more than 800 human subjects have been treated' (filed 2026-05-12)
- Newer filing adds: 'we have seen no serum sickness rate and no incidence of neutralizing anti-drug antibodies (ADA)' statement (filed 2026-05-12)
- Newer filing adds: expanded regulatory pathway discussion mentioning FDA, MHRA, and TGA (filed 2026-05-12)
- Newer filing adds: detailed explanation of CBER vs CDER regulatory distinction for polyclonal vs monoclonal antibodies (filed 2026-05-12)
- Removed:
- Older filing contained: 'hIgGs' instead of 'hIgG' in Company Overview (filed 2025-11-14)
- Older filing contained: reference to 'internally discovered antibodies' and specific description of multi-specificity in Company Overview (filed 2025-11-14)
- Older filing contained: 'without the need for human donors or convalescent plasma' in Company Overview opening (filed 2025-11-14)
- Older filing contained: 'first-in-class, multi-target hATG treatment designed to provide superior efficacy and safety' descriptor (filed 2025-11-14)
- Older filing contained: reference to Stage 2 T1D in SAB-142 indication (filed 2025-11-14)
- Older filing contained: reference to 'more than 700 human subjects' treated with platform antibodies (filed 2025-11-14)
- Older filing contained: 'support the expectation of a zero-serum sickness rate and a zero incidence' language (filed 2025-11-14)
- Older filing contained: detailed references to IND clearance date (May 2024), Phase 1 positive data announcement (January 2025), and FDA Type B meeting (May 29, 2025) (filed 2025-11-14)
- Older filing contained: reference to SAFEGUARD study design discussion and FDA guidance (filed 2025-11-14)
- Older filing contained: 'Other Immunology Indications' section discussing T- and B-cell dysregulation in 80+ autoimmune diseases (filed 2025-11-14)
- Reworded:
- Changed from 'involved known and unknown risks' to 'involve known and unknown risks' in forward-looking statements section (filed 2026-05-12)
- Shifted Company Overview description: moved 'without the need for human donors or convalescent plasma' from opening sentence to later in proprietary platform discussion (filed 2026-05-12)
- Changed SAB-142 description from 'human anti-thymocyte globulin (hATG) focused on preventing or delaying' to 'a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D)' (filed 2026-05-12)
- Removed 'first-in-class, multi-target hATG treatment designed to provide superior efficacy and safety in delaying the onset or progression of T1D' language and replaced with mechanistic/clinical validation focus (filed 2026-05-12)
- Changed indication scope from 'Stage 3 or Stage 2 T1D' to focus on 'Stage 3 T1D patients' only (filed 2026-05-12)
- Changed from 'Tc Bovine' to 'Tc-Bovine' hyphenation (filed 2026-05-12)
- Notes:
- The newer filing text appears truncated at the end of the SAB-142 section, cutting off mid-sentence regarding regulatory pathway details
- The older filing text also appears truncated at the end, cutting off discussion of Phase 2 progression in other indications
- Full comparison of remaining MD&A sections not possible due to truncation in both documents
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for SABS — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding SABS as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 3,884,557
- Reported value $15,149,771
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SABS's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SABS had 3,603,065 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
SABS had 3.96% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.37 days to cover at the same settlement.
- Reported short interest (shares) 3,603,065
- Short interest (% of shares outstanding) 3.96%
- Prior settlement (shares) 4,121,534
- Reported change -12.58%
- Days to cover (reported) 13.37
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Provention Bio (Sanofi)
- MacroGenics (MGNX)
- Viatris (VTRS)
- Amgen (AMGN)
- Takeda Pharmaceutical (TAK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SABS vs…
SAB BIOTHERAPEUTICS INC is found in…
Frequently asked questions
What does SAB BIOTHERAPEUTICS INC (SABS) do?
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing multi-specific, human immunoglobulin G (hIgG) therapeutics for immune and autoimmune disorders. The company utilizes a proprietary transchromosomic cattle (Tc-Bovine) platform to produce high-potency, disease-targeted human antibodies without the need for human plasma donors. Its lead product candidate, SAB-142, is currently in clinical development as a disease-modifying immunotherapy for type 1 diabetes.
What sector is SAB BIOTHERAPEUTICS INC (SABS) in?
SAB BIOTHERAPEUTICS INC (SABS) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are SAB BIOTHERAPEUTICS INC's (SABS) competitors?
Notable peers of SAB BIOTHERAPEUTICS INC (SABS) include Provention Bio (Sanofi), MacroGenics, Viatris, Amgen and Takeda Pharmaceutical. This peer set is informational only — not financial advice.
Is SAB BIOTHERAPEUTICS INC (SABS) overbought or oversold right now?
SAB BIOTHERAPEUTICS INC (SABS) is currently in oversold territory (its 14-day RSI is 29, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SABS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.